908 Devices to Participate in Upcoming November 2022 Investor Conferences

908 Devices Inc., a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, announced it will participate in the following investor conferences in New York, NY.

BOSTON--(BUSINESS WIRE)-- 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it will participate in the following investor conferences in New York, NY.

  • Stifel 2022 Healthcare Conference
    Fireside Chat on Wednesday, November 16th at 1:15 p.m. Eastern Time / 10:15 a.m. Pacific Time
  • Canaccord Genuity MedTech, Diagnostics, and Digital Health & Services Forum
    Fireside Chat on Thursday, November 17th at 10:00 a.m. Eastern Time / 7:00 a.m. Pacific Time

Interested parties may access a live and archived webcast of the virtual sessions on the “Investors” section of the company website at: www.908devices.com.

About 908 Devices

908 Devices Inc. (Nasdaq: MASS) is democratizing laboratory mass spectrometry with its simple handheld and desktop devices, addressing critical-to-life applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in life sciences research, bioprocessing, pharma / biopharma, forensics and adjacent markets. The Company is headquartered in the heart of Boston, where it designs and manufactures innovative products that bring together the power of mass spectrometry, microfluidic separations, software automation and machine learning.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221102005024/en/

Contacts

Media
Barbara Russo
brusso@908devices.com

Investor
Carrie Mendivil
IR@908devices.com

Source: 908 Devices Inc

Powered by Business Wire

View this news release online at:
http://www.businesswire.com/news/home/20221102005024/en

MORE ON THIS TOPIC